Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
Ulcerative Colitis
Interventions
DRUG

mesalamine

mesalamine 2.4 g/day (400 mg tablet) for 6 weeks

DRUG

mesalamine

mesalamine 4.8 g/day (800 mg tablet) for 6 weeks

Trial Locations (44)

Unknown

Research Site, Birmingham

Research Site, Anaheim

Research Site, Sacramento

Research Site, San Francisco

Research Site, Denver

Research Facility, Golden

Research Site, Bridgeport

Research Site, Fort Myers

Research Site, Hollywood

Research Site, Jupiter

Research Site, Miami

Research Facility, Atlanta

Research Facility, Decatur

Research Site, Arlington Heights

Research Site, Moline

Research Site, Rockford

Research Site, Wichita

Research Site, Metairie

Research Site, Baltimore

Research Site, Laurel

Research Site, Detroit

Research Site, New Brunswick

Research Site, Somerville

Research Site, Great Neck

Research Site, Pomona

Research Facility, Poughkeepsie

Research Site, Raleigh

Research Site, Winston-Salem

Research Site, Cincinnati

Research Site, Tulsa

Research Site, Philadelphia

Research Site, Pittsburgh

Research Site, Charleston

Research Facility, Memphis

Research Facility, Nashville

Research Site, Fort Worth

Research Site, Houston

Research Site, San Antonio

Research Site, Burlington

Research Site, Charlottesville

Research Facility, Falls Church

Research Site, Norfolk

Research Site, Tacoma

Research Site, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Warner Chilcott

INDUSTRY

NCT00577473 - Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I) | Biotech Hunter | Biotech Hunter